10x Genomics (TXG) Stock Forecast & Price Target $23.68 -1.00 (-4.05%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.86 +0.18 (+0.78%) As of 05/22/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock 10x Genomics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 15 Analyst RatingsSell1Hold10Buy4 Based on 15 Wall Street analysts who have issued ratings for 10x Genomics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 1 has given a sell rating, 10 have given a hold rating, and 4 have given a buy rating for TXG. Consensus Price Target $23.17-2.17% Downside According to the 15 analysts' twelve-month price targets for 10x Genomics, the average price target is $23.17. The highest price target for TXG is $32.00, while the lowest price target for TXG is $17.00. The average price target represents a forecasted downside of -2.17% from the current price of $23.68. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for TXG and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 10x Genomics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXG Analyst Ratings Over TimeTypeCurrent Forecast5/23/25 to 5/23/261 Month Ago4/23/25 to 4/23/263 Months Ago2/22/25 to 2/22/261 Year Ago5/23/24 to 5/23/25Strong Buy0 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy4 Buy rating(s)5 Buy rating(s)4 Buy rating(s)7 Buy rating(s)Hold10 Hold rating(s)9 Hold rating(s)9 Hold rating(s)7 Hold rating(s)Sell1 Sell rating(s)2 Sell rating(s)3 Sell rating(s)2 Sell rating(s)Consensus Price Target$23.17$20.82$18.11$15.81Forecasted Upside-2.17% Downside-2.79% Downside-4.09% Downside93.48% UpsideConsensus RatingHoldHoldHoldHold TXG Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History TXG Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table 10x Genomics Stock vs. The CompetitionType10x GenomicsMedical CompaniesBroader MarketConsensus Rating Score 2.20 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside-2.17% Downside1,714.95% Upside15.09% UpsideNews Sentiment RatingVery Negative NewsSee Recent TXG NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/18/2026 Zacks ResearchNot Rated DowngradeStrong-Buy ➝ Hold5/12/2026 Morgan Stanley3 of 5 starsTejas Savant4 of 5 starsBoost TargetEqual Weight$20.00 ➝ $22.00+5.47%5/12/2026 JPMorgan Chase & Co.3 of 5 starsCasey WoodringNot RatedBoost TargetNeutral$17.00 ➝ $20.00-4.76%4/20/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKyle MiksonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$22.00 ➝ $32.00+26.72%4/20/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDerik DeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$21.00 ➝ $30.00+17.30%4/14/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLuke SergottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$22.00 ➝ $30.00+27.23%4/7/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPatrick DonnellySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$18.00 ➝ $24.00+10.57%3/31/2026 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt LarewSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/27/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingSell (D-)3/2/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDaniel AriasSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$20.00 ➝ $25.00+8.46%ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.See the 5 stocks to avoid2/20/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDan LeonardSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$14.00 ➝ $20.00+4.22%2/13/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJustin BowersSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetHold$17.00-11.76%2/13/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDan BrennanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetHold$18.00 ➝ $19.00-1.38%1/27/2026 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike KratkySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetMarket Perform$22.00 ➝ $20.00-9.02%11/11/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid WestenbergSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$15.00 ➝ $19.00+10.88%5/15/2025 StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMason CarricoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$14.00 ➝ $14.00+53.01%5/12/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew SykesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSell$7.50 ➝ $6.50-31.40%7/22/2024 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Buy$24.00 ➝ $24.00+43.71%6/27/2024 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDoug SchenkelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform6/25/2024 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSubbu NambiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:27 PM ET. TXG Forecast - Frequently Asked Questions What is 10x Genomics' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for 10x Genomics is $23.17, with a high forecast of $32.00 and a low forecast of $17.00. Should I buy or sell 10x Genomics stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There is currently 1 sell rating, 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares. Does 10x Genomics's stock price have much downside? According to analysts, 10x Genomics's stock has a predicted downside of -2.17% based on their 12-month stock forecasts. Has 10x Genomics been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, 10x Genomics's stock had 2 upgrades and 1 downgrade by analysts. What analysts cover 10x Genomics? 10x Genomics has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, Weiss Ratings, William Blair, and Zacks Research in the past 90 days. Do Wall Street analysts like 10x Genomics more than its competitors? Analysts like 10x Genomics less than other "medical" companies. The consensus rating score for 10x Genomics is 2.20 while the average consensus rating score for "medical" companies is 2.30. Learn more on how TXG compares to other companies. Stock Forecasts and Research Tools Related Companies PACB Stock Forecast RVTY Stock Forecast CAMT Stock Forecast ST Stock Forecast RAL Stock Forecast AVTR Stock Forecast MIR Stock Forecast VNT Stock Forecast AEHR Stock Forecast ALMR Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With 10x Genomics RecommendationsZacks ResearchMorgan StanleyJPMorgan Chase & Co.Canaccord Genuity GroupBank of AmericaBarclaysCitigroupWilliam BlairWeiss RatingsStifel NicolausUBS GroupTD CowenDeutsche Bank AktiengesellschaftLeerink PartnersWall Street Zen This page (NASDAQ:TXG) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
